BioPath

Latest News
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia PatientsAug 24 2021
Bio-Path Holdings Reports Second Quarter 2021 Financial ResultsAug 13 2021
Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021Aug 6 2021
Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003Jun 22 2021
Bio-Path Holdings Reports First Quarter 2021 Financial ResultsMay 14 2021
Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021May 7 2021
Bio-Path Announces Publication in BiomedicinesApr 22 2021
Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual MeetingApr 12 2021
Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid LeukemiaApr 5 2021
Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual MeetingMar 11 2021
BIO-PATH HOLDINGS REPORTS FULL YEAR 2020 FINANCIAL RESULTSMar 10 2021
Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021Mar 3 2021
Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common StockFeb 18 2021
Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common StockFeb 16 2021
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common StockFeb 13 2021
Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform TechnologyFeb 10 2021
Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002Nov 19 2020
BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTSNov 13 2020
Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020Nov 6 2020
Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of CancersOct 22 2020

More News

Giving Previously Untreatable Cancer Patients a Fighting Chance

We are developing targeted cancer treatments that offer effective therapy without harsh side effects so that even the most fragile patients can have tolerable treatment options.

About Us

DNAbilize^®

The company’s lead candidate is prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, for the treatment of acute myeloid leukemia (AML). Prexigebersen is being assessed in a Phase 2 trial in combination with front-line therapy.

Learn More

Our Patients

Prognosis for these older cancer patients remains very poor. Bio-Path aims to meet the need that exists for non-toxic therapies for older, fragile cancer patients who are unfit or ineligible for high-dose chemotherapy.

A new path in DNA-powered medicine.

Latest News

Giving Previously Untreatable Cancer Patients a Fighting Chance

DNAbilize^®

Our Patients

Our Products

Delivering a Better Path for Cancer Patients.

Latest News

Giving Previously Untreatable Cancer Patients a Fighting Chance

DNAbilize®

Our Patients

Our Products

Delivering a Better Path for Cancer Patients.

DNAbilize^®